会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明专利
    • Improvements in windows for ships, carriages, and the like
    • GB210174A
    • 1924-01-28
    • GB2949422
    • 1922-10-28
    • DENNYSTOWN BRASS WORKS LTDJOHN MCPHERSON
    • B63B19/00
    • 210,174. Dennystown Brass Works, Ltd., and McPherson, J. Oct. 28, 1922. Cabin and deck lights.-The sliding window A works in vertical channel-section side members A , A which are carried in the framing A of the window. The side members have at their lower ends a transverse elongated slot A in which works a pin B carried by crank arms B' scoured one at each end of a transverse shaft B which is free to oscillate in brackets B , B secure on the face of the framing. In the side members are diagonal cam slots C which engage pins C projecting inwards from the framing A . Depressing the handle B causes upward movement of the side members A , A which are simultaneously moved laterally by the action of the pins C to cause the window to engage with a rubber-faced seating C . The invention consists in balancing the glass by spring-controlled means comprising a pair of levers D , D each pivoted at their lower ends to downwardextensions of the framing. The upward extension of these arms carry rollers D , D which support the lower edge of the glass. To the lower curved part of the lever D and to a lever D on the lever D are attached springs E , E proportioned to balance the glass in all positions. The upper ends of the springs are attached to arms G on the transverse shaft B so as to tend to move the side members A , A towards the frame.
    • 4. 发明授权
    • &dgr;-sarcoglycan antibodies
    • δ-糖聚糖抗体
    • US06211340B1
    • 2001-04-03
    • US09119827
    • 1998-07-21
    • Kevin P. CampbellDaniel JungFranck DuclosVolker StraubJohn McPherson
    • Kevin P. CampbellDaniel JungFranck DuclosVolker StraubJohn McPherson
    • C07K1618
    • C07K14/4707
    • Disclosed herein is a substantially pure nucleic acid sequence encoding a mammalian 35 kDa non-dystrophin component (&dgr;-sarcoglycan) of the dystrophin-glycoprotein complex. Also disclosed are the amino acid sequence and an immunogenic peptide of &dgr;-sarcoglycan. The peptide when used to immunize a mammal, stimulates the production of antibodies which bind specifically to the &dgr;-sarcoglycan. Methods to identify mutations in the &dgr;-sarcoglycan gene associated with autosomal recessive limb-girdle muscular dystrophy are also disclosed. The identification of such mutations enables the design of nucleic acid probes which hybridize specifically to a mutant form of &dgr;-sarcoglycan, or the complement thereof, but not to the DNA of the wild-type form of the gene (or the complement thereof), under stringent hybridization conditions. Such probes are useful, for example, in connection with the diagnosis of autosomal recessive limb-girdle muscular dystrophy. In addition, the identification of such mutations enables the diagnosis of autosomal recessive limb-girdle muscular dystrophy through the use of direct DNA sequencing techniques.
    • 本文公开了编码肌营养不良蛋白 - 糖蛋白复合物的哺乳动物35kDa非肌营养不良蛋白成分(δ-莽草酸)的基本上纯的核酸序列。 还公开了δ-色氨酸的氨基酸序列和免疫原性肽。 当肽用于免疫哺乳动物时,刺激产生与δ-糖聚糖特异性结合的抗体。 还公开了鉴定与常染色体隐性遗传性肢体肌营养不良症相关的δ-色氨酸聚糖基因突变的方法。 这种突变的鉴定使得能够设计特异性地与δ-色氨酸聚糖或其互补体的突变形式杂交的核酸探针,而不与野生型形式的基因(或其互补物)的DNA杂交, 在严格的杂交条件下。 这样的探针可用于例如与常染色体隐性性腰带肌营养不良症的诊断有关。 此外,通过使用直接DNA测序技术,鉴定这种突变能够诊断常染色体隐性的腰带肌营养不良症。
    • 9. 发明申请
    • LIFE SETTLEMENT METHOD AND APPARATUS
    • 生活解决方法和设备
    • US20080177582A1
    • 2008-07-24
    • US12015108
    • 2008-01-16
    • Michael O'BrienJohn McPhersonSam BeritelaMichael Quinn
    • Michael O'BrienJohn McPhersonSam BeritelaMichael Quinn
    • G06Q40/00
    • G06Q40/08
    • Methods and devices for reducing costs associated with life settlement transactions include an initial economic evaluation and a targeted but abbreviated verification of information provided by a potential customer and gathering of additional information, followed by a conditional offer for those policies that satisfy the economic criteria (e.g., face value of policy, stated life expectancy, etc.) and for which the abbreviated verification is positive. The verification and additional information may be performed by one or more of following: 1) a query of a prescription database in which the identity and use of the prescription drugs identified by the customer are determined; 2) a questionnaire filled out by a physician treating the patient for a particular illness; and 3) a telephone inquiry of the insured. If the additional information and verification are consistent with the initial information, the life settlement is completed.
    • 用于降低与人寿结算交易相关的成本的方法和设备包括初始经济评估,潜在客户提供的信息的有针对性但缩写的验证,并收集附加信息,其次是满足经济标准的政策的有条件报价(例如 ,政策的面值,预期寿命等),缩写验证是正面的。 验证和附加信息可以通过以下一个或多个来执行:1)查询由客户确定的处方药的身份和使用确定的处方数据库; 2)医生为特定疾病治疗患者填写的问卷; 和3)被保险人的电话查询。 如果附加信息和验证与初始信息一致,则结算生命周期。